ABSTRACT
Background Most seasonally circulating enteroviruses result in asymptomatic or mildly symptomatic infections. In rare cases, however, infection with some subtypes can result in paralysis or death. Of the 300 subtypes known, only poliovirus is reportable, limiting our understanding of the distribution of other enteroviruses that can cause clinical disease.
Objective The overarching objectives of this study were to: 1) describe the distribution of enteroviruses in Arizona during the late summer and fall of 2022, the time of year when they are thought to be most abundant, and 2) demonstrate the utility of viral pan-assay approaches for semi-agnostic discovery that can be followed up by more targeted assays and phylogenomics.
Methods This study utilizes pooled nasal samples collected from school-aged children and long-term care facility residents, and wastewater from multiple locations in Arizona during July–October of 2022. We used PCR to amplify and sequence a region common to all enteroviruses, followed by species-level bioinformatic characterization using the QIIME 2 platform. For Enterovirus-D68 (EV-D68), detection was carried out using RT-qPCR, followed by confirmation using near-complete whole EV-D68 genome sequencing using a newly designed tiled amplicon approach.
Results In the late summer and early fall of 2022, multiple enterovirus species were identified in Arizona wastewater, with Coxsackievirus A6, EV-D68, and Coxsackievirus A19 composing 86% of the characterized reads sequenced. While EV-D68 was not identified in pooled human nasal samples, and the only reported acute flaccid myelitis case in Arizona did not test positive for the virus, an in-depth analysis of EV-D68 in wastewater revealed that the virus was circulating from August through mid-October. A phylogenetic analysis on this relatively limited dataset revealed just a few importations into the state, with a single clade indicating local circulation.
Significance This study further supports the utility of wastewater-based epidemiology to identify potential public health threats. Our further investigations into EV-D68 shows how these data might help inform healthcare diagnoses for children presenting with concerning neurological symptoms.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Support for this work included funding from the National Institute of Allergy and Infectious Diseases at the National Institutes of Health (R15AI156771) to TRP, the Centers for Disease Control and Prevention (75D30121C11191) to TRP, Northern Arizona University Urdea Collaborative Research Award from the Office of Undergraduate Research and Creative Activity to KMS, 2022-309890 from the Chan Zuckerberg Initiative DAF an advised fund of the Silicon Valley Community Foundation to JGC, The NARBHA Institute to DME, the Arizona Board of Regents to Dr. Paul Keim (supported work on this project by JS) and the Centers for Disease Control and Prevention Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases funding to the Arizona Department of Health Services with a subaward to CMH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Board of Northern Arizona University gave ethical approval for this work (Project 1766728). Institutional Review Board of Northern Arizona Healthcare gave ethical approval for this work (2023-014-FMC).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Sections "Application of a New Tiled Amplicon Sequencing Scheme" and "Application of a New Tiled Amplicon Sequencing Scheme on Wastewater Samples" added to further describe the efficacy of the new primer scheme used as part of this study. New Table 1 added to further elaborate on the efficacy of the newly designed primer scheme. New Figure 5 added to accompany section "Efficacy of a New Tiled Amplicon Sequencing Scheme". New Supplementary Table 5 added to show sequencing performance on samples and positive controls. Figures 3 and 4 revised to further clarify findings. Discussion and supplemental files updated to further elaborate on the impact of our findings.
